FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to the field of medicine, namely to a drug for the prevention or treatment of cardiovascular diseases containing a first layer containing fimasartan potassium trihydrate, and a second layer containing rosuvastatin calcium, and amlodipine bezilate, where the second layer contains low-substituted hydroxypropyl cellulose.
EFFECT: present invention provides for the creation of a combined drug for the effective treatment of cardiovascular diseases containing fimasartan, amlodipine and rosuvastatin as effective components, which demonstrates an excellent dissolution profile and stability and improves patient compliance with the therapy regimen.
7 cl, 3 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| TABLET AND METHOD OF ITS PREPARATION | 2019 |
|
RU2796301C2 |
| PHARMACEUTICAL COMBINATION FORMULATION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2014 |
|
RU2660586C1 |
| PHARMACEUTICAL COMPOSITION COMPRISING FIMASARTAN AND HYDROCHLOROTHIAZIDE | 2013 |
|
RU2613900C2 |
| PHARMACEUTICAL COMPLEX COMPOSITION CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN | 2016 |
|
RU2724338C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETIC NEPHROPATHY | 2016 |
|
RU2702117C1 |
| TABLET AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2697660C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT | 2013 |
|
RU2616516C2 |
| DOSAGE FORM WITH IMPROVED CHARACTERISTICS OF pH-DEPENDENT RELEASE OF PREPARATION CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2716025C1 |
| TREATMENT OF BIPOLAR DISORDERS AND ACCOMPANYING SYMPTOMS | 2005 |
|
RU2403039C2 |
